Paul Berns and Laura Deming
February 8, 2022 05:00 AM ESTUpdated 06:50 AM
Startups

Ex­clu­sive: ARCH-backed ex­er­cise-in-a-pill start­up qui­et­ly laid off half its staff, ‘ful­ly piv­ot­ed’ in Oc­to­ber

Jason Mast

Editor

In De­cem­ber 2019, a tiny decade-old Cal­i­for­nia start­up known as Cardero Ther­a­peu­tics an­nounced a new name — Epir­i­um Bio — a new di­rec­tion and $85 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times